B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Henry Schein, Inc. (NASDAQ:HSIC – Free Report) during the 3rd quarter, Holdings Channel reports. The firm purchased 7,062 shares of the company’s stock, valued at approximately $515,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HSIC. Pathstone Holdings LLC increased its position in shares of Henry Schein by 3.1% in the third quarter. Pathstone Holdings LLC now owns 24,028 shares of the company’s stock valued at $1,752,000 after acquiring an additional 732 shares during the last quarter. Banyan Capital Management Inc. grew its stake in Henry Schein by 1.9% in the third quarter. Banyan Capital Management Inc. now owns 127,434 shares of the company’s stock valued at $9,290,000 after purchasing an additional 2,351 shares in the last quarter. Clarkston Capital Partners LLC increased its position in shares of Henry Schein by 5.4% during the 3rd quarter. Clarkston Capital Partners LLC now owns 1,397,805 shares of the company’s stock worth $101,900,000 after purchasing an additional 71,560 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Henry Schein by 1,848.9% during the 3rd quarter. Thrivent Financial for Lutherans now owns 105,415 shares of the company’s stock worth $7,685,000 after purchasing an additional 100,006 shares in the last quarter. Finally, Natixis Advisors LLC boosted its holdings in shares of Henry Schein by 18.8% in the 3rd quarter. Natixis Advisors LLC now owns 81,877 shares of the company’s stock valued at $5,969,000 after buying an additional 12,930 shares during the last quarter. 96.62% of the stock is owned by institutional investors.
Henry Schein Trading Up 1.8 %
HSIC stock opened at $75.08 on Monday. Henry Schein, Inc. has a 52 week low of $63.67 and a 52 week high of $82.63. The company has a market capitalization of $9.36 billion, a PE ratio of 30.90, a price-to-earnings-growth ratio of 2.12 and a beta of 0.87. The company’s 50-day simple moving average is $70.89 and its 200 day simple moving average is $69.73. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42.
Insider Buying and Selling at Henry Schein
In other news, SVP Lorelei Mcglynn sold 21,035 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the transaction, the senior vice president now directly owns 71,833 shares in the company, valued at approximately $4,978,026.90. The trade was a 22.65 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Michael S. Ettinger sold 12,240 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the sale, the chief operating officer now directly owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. This trade represents a 12.25 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.
Analyst Upgrades and Downgrades
HSIC has been the topic of a number of recent analyst reports. StockNews.com upgraded shares of Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Barrington Research reaffirmed an “outperform” rating and issued a $82.00 target price on shares of Henry Schein in a report on Wednesday, November 6th. Robert W. Baird reduced their price target on Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. JPMorgan Chase & Co. dropped their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Finally, Evercore ISI raised their price objective on Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research report on Tuesday, October 8th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Henry Schein presently has an average rating of “Moderate Buy” and a consensus target price of $78.89.
Check Out Our Latest Report on HSIC
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
See Also
- Five stocks we like better than Henry Schein
- Short Selling: How to Short a Stock
- Disney’s Magic Strategy: Reinventing the House of Mouse
- Dividend Capture Strategy: What You Need to Know
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- What is a SEC Filing?
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC – Free Report).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.